We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · July 06, 2018

Enzalutamide Decreases Risk of Metastasis and Death in Men With Nonmetastatic CRPC

The New England Journal of Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

The New England Journal of Medicine
Enzalutamide in Men With Nonmetastatic, Castration-Resistant Prostate Cancer
N. Engl. J. Med 2018 Jun 28;378(26)2465-2474, M Hussain, K Fizazi, F Saad, P Rathenborg, N Shore, U Ferreira, P Ivashchenko, E Demirhan, K Modelska, Phung, A Krivoshik, CN Sternberg

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading